Wisp, Visby Medical Partner on STI Test

Wisp and Visby Medical are teaming up to expand access to the latter’s U.S. Food and Drug Administration (FDA)-authorized at-home PCR STI test, with Wisp providing follow-up telehealth care for patients who test positive for chlamydia, gonorrhea, or trichomoniasis.

According to the World Health Organization, more than 1 million curable sexually transmitted infections (STIs) are acquired daily worldwide among people aged 15–49, and most are without symptoms. These infections can lead to lasting health effects if left untreated—in fact, nearly 100,000 U.S. women lose their fertility annually due to complications from untreated STIs. Recognizing the overlap with their patient populations, Wisp and Visby aim to meet this treatment need by making STI testing discreet, accessible, and significantly faster than conventional care pathways. The program will initially be offered through targeted patient outreach, with plans to expand access over time.

The palm-sized Women’s Sexual Health PCR test delivers lab-quality results in 30 minutes through Visby’s mobile app. Patients who test positive are referred to Wisp and receive a complimentary virtual consultation with a licensed Wisp provider, and when clinically appropriate, antibiotics are prescribed immediately, all from the privacy of home.

“This partnership came directly from listening to our patients,” Wisp CEO Monica Cepak stated. “Women are asking for faster answers and more seamless next steps. By pairing Visby’s FDA-authorized at-home PCR test with Wisp’s care model, we’re delivering on our mission to support women across every life stage with fast, private, and stigma-free care.”

Chlamydia, gonorrhea, and trichomoniasis are the most common curable STIs and can be treated effectively with antibiotics. Wisp’s platform removes barriers to care through secure online consultations with a licensed medical provider, personalized care plans, and confidential treatment pathways. The test is an eligible expense for both FSA and HSA accounts.

“By providing timely medical advice through telehealth, the value of the Visby at-home sexual health test significantly increases,” Visby Medical Chief Medical Officer Dr. Gary Schoolnik, a professor of Medicine at Stanford Medical School. “This ensures that women who use the Visby test will receive prompt and effective advice and a path to treatment, if indicated.”

Wisp and Visby plan to expand access to this integrated testing and care model. As demand for discreet, at-home healthcare solutions grows, the partnership reflects a shared commitment to reimagining sexual health care with speed, accessibility, and patient-centered design at the core.

Founded in 2012, Visby Medical is striving to revolutionize infectious disease diagnosis by empowering physicians and patients to accurately test for infections anywhere, anytime, with laboratory accuracy. The company’s proprietary technology platform delivers true PCR results in under 30 minutes through the world’s first instrument-free, single-use PCR tests that fit in the palm of the hand. Visby is actively working to expand its platform by developing a broader menu of tests for at-home setting.

Wisp is the largest U.S. pure play women’s telehealth provider, serving more than 1.8 million patients nationwide. Offering discreet, online care and a comprehensive range of first-to-market products, Wisp addresses women’s health needs across every stage of life—from birth control to fertility, menopause, STI testing, and at-home diagnostics. The company was recognized by Inc. as Best in Business 2025, TIME as Best Inventions of 2025, and Clio as Best Campaign in Health Equity of 2025. Wisp is majority-owned by WELL Health Technologies Corp.